Maxim Group Reaffirms Hold Rating for Virpax Pharmaceuticals (NASDAQ:VRPX)

Virpax Pharmaceuticals (NASDAQ:VRPX)‘s stock had its “hold” rating reissued by equities research analysts at Maxim Group in a research report issued to clients and investors on Wednesday, Benzinga reports.

Virpax Pharmaceuticals Trading Down 1.6 %

Virpax Pharmaceuticals stock opened at $0.48 on Wednesday. Virpax Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $8.48. The firm has a 50 day moving average price of $0.83 and a 200 day moving average price of $1.50.

Virpax Pharmaceuticals (NASDAQ:VRPX) last posted its quarterly earnings data on Monday, August 12th. The company reported ($1.75) earnings per share (EPS) for the quarter.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.